Canaccord Genuity downgrades ResMed to Hold from Buy

What happened

Canaccord Genuity downgraded ResMed from Buy to Hold. The article also lists four other recent analyst actions, all dated October 30, with ratings ranging from Neutral to Outperform and price targets from $250 to $288.

Confirmed

Global impact / market context

A downgrade from Buy to Hold signals that Canaccord sees less reason to expect ResMed shares to outperform, potentially reducing investor demand. If other analysts also become less positive, ResMed could face pressure to attract buyers, though the article reports no share-price reaction.

Analyst inference

The article reports four recent analyst targets between $250 and $288, alongside ratings ranging from Neutral to Outperform and Overweight. If investors use these opinions to guide their positioning, differing views could influence demand for ResMed shares, but no share-price response is reported.

Analyst inference

What to watch

1. Watch for further ResMed rating changes: several downgrades could signal weakening analyst expectations and make it harder for the company to attract investor demand. Analyst inference
2. Compare future price targets with the listed $250–$288 range to see whether analysts are raising or lowering their expectations for ResMed. Analyst inference
3. The article reports no company results, business changes, or share-price response, so it does not establish whether this downgrade reflects new operating information. Confirmed

Evidence

• Original source link unavailable